NCT02149537View on ClinicalTrials.gov

Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

December 31, 2022

Conditions
Sickle Cell DiseaseSickle Cell Anemia
Interventions
DRUG

hydroxyurea

Trial Locations (1)

Unknown

University of Ibadan College of Medicine, Ibadan

All Listed Sponsors
collaborator

University of Illinois at Chicago

OTHER

collaborator

University of Ibadan

OTHER

lead

Loyola University

OTHER

NCT02149537 - Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment | Biotech Hunter | Biotech Hunter